Welcome to our dedicated page for Invivyd SEC filings (Ticker: IVVD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Invivyd, Inc. filings document material events, governance matters, capital actions, and financial-result disclosures for a Nasdaq-listed biopharmaceutical company developing monoclonal antibodies for serious viral infectious diseases. Recent Form 8-K reports furnish operating results, preliminary product revenue information for PEMGARDA, corporate presentations, and program updates involving COVID-19, RSV, and measles antibody candidates.
The filing record also includes a definitive proxy statement covering annual-meeting matters such as director elections and auditor ratification, as well as an 8-K describing a completed underwritten public offering of common stock and pre-funded warrants. These disclosures describe the company’s common stock, financing activity, board governance, research and development priorities, and commercial preparedness around its antibody portfolio.
BlackRock, Inc. reported a passive ownership position in Invivyd, Inc. common stock on Schedule 13G. BlackRock and certain of its business units beneficially own 16,124,696 shares of Invivyd common stock, representing 5.5% of the outstanding class.
BlackRock has sole voting power over 15,974,045 shares and sole dispositive power over all 16,124,696 shares, with no shared voting or dispositive power. Various underlying clients have economic rights to dividends and sale proceeds, but no single client holds more than five percent of Invivyd’s outstanding common shares.
Invivyd, Inc. disclosed that it received a Nasdaq deficiency letter because its common stock failed to meet the $1.00 per share minimum bid price requirement for 30 consecutive business days for listing on The Nasdaq Global Market.
The company has until January 19, 2027 to regain compliance by having a closing bid of at least $1.00 for a minimum of ten consecutive business days, subject to Nasdaq’s discretion to extend that period. If compliance is not regained, Invivyd may seek a second 180‑day compliance period by transferring to the Nasdaq Capital Market and meeting other listing criteria, but its stock could ultimately be subject to delisting, with only a right to appeal to a Nasdaq Hearings Panel. Invivyd plans to monitor its share price and consider available options but provides no assurance it will regain compliance.
Invivyd, Inc. reported that the U.S. Food and Drug Administration has issued a Notice of Termination for the Emergency Use Authorization (EUA) of its COVID-19 monoclonal antibody PEMGARDA, with termination effective on June 29, 2027, following an HHS decision to end the COVID-19 EUA declaration.
PEMGARDA will remain authorized during a twelve-month transition period while Invivyd continues discussions with FDA on potential next steps and a possible Biologics License Application. The company emphasizes PEMGARDA’s role in pre-exposure COVID-19 prevention for moderately to severely immunocompromised patients and highlights existing clinical, safety, and real-world use data.
Invivyd, Inc. director Ajay Royan received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $1.04 per share and expire on May 18, 2036. They vest in full on the earlier of May 19, 2027 or the company’s 2027 annual stockholders meeting, subject to Royan’s continuous service. Following this grant, he holds 50,000 options directly.
Invivyd, Inc. director Kevin F. McLaughlin received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $1.04 per share and expire on May 18, 2036. They vest in full on the earlier of May 19, 2027 or the company’s 2027 Annual Meeting of Stockholders, conditioned on his continuous service through that vesting date.
Invivyd, Inc. director Terrance McGuire received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $1.04 per share and expire on May 18, 2036. All 50,000 options were reported as directly owned following this grant.
According to the award terms, the option vests in full on the earlier of May 19, 2027 or the date of Invivyd’s 2027 annual meeting of stockholders, as long as McGuire continues to serve the company through that vesting date. This is a compensation-related grant, not an open‑market purchase or sale.
Invivyd, Inc. reported that director Marc Elia received a grant of stock options covering 50,000 shares of common stock at an exercise price of $1.04 per share. The options vest in full on the earlier of May 19, 2027 or the company’s 2027 Annual Meeting of Stockholders, subject to his continuous service, and expire on May 18, 2036. Following this award, Elia holds 50,000 stock options, which he is deemed to hold for the benefit of M28 Capital Management LP and funds managed by that firm.
Invivyd, Inc. reported that director Paul Bolno received a grant of stock options covering 32,876 shares of common stock. The options have an exercise price of $1.04 per share and expire on May 18, 2036. The grant vests in full on the earlier of May 19, 2027 or the date of Invivyd's 2027 Annual Meeting of Stockholders, provided he continues in service through that vesting date. After this grant, Bolno holds options for 32,876 underlying shares directly.
Invivyd, Inc. director Tamsin Berry received a compensation-related stock option grant covering 50,000 shares of common stock. The option has an exercise price of $1.0400 per share and expires on May 18, 2036. It vests in full on the earlier of May 19, 2027 or the company’s 2027 Annual Meeting of Stockholders, subject to her continuous service through the vesting date. Following this grant, she holds stock options for 50,000 shares directly.
Invivyd, Inc. reported voting results from its Annual Meeting of Stockholders held on May 19, 2026. Stockholders elected six directors — Tamsin Berry, Paul B. Bolno, M.D., Marc Elia, Terrance McGuire, Kevin F. McLaughlin and Ajay Royan — each for a one-year term ending at the 2027 annual meeting.
Each director nominee received over 173 million votes in favor, with additional broker non-votes recorded. Stockholders also ratified PricewaterhouseCoopers LLP as Invivyd’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 222,576,623 votes for, 80,390 against and 44,315 abstentions.